Clinical and methodological factors affecting non-transferrin-bound iron values using a novel fluorescent bead assay  by Garbowski, Maciej W. et al.
ORIGINAL ARTICLES
Clinical and methodological factors affecting
non-transferrin-bound iron values using a novel
fluorescent bead assayMACIEJ W. GARBOWSKI1, YONGMIN MA1, SUTHAT FUCHAROEN,
SOMDET SRICHAIRATANAKOOL, ROBERT HIDER, and JOHN B. PORTER
LONDON, UK; HANGZHOU, CHINA; SALAYA AND CHIANGMAI, THAILAND1Maciej W. Garbowski and Yongm
work.
From the Research Haematology
University College London, UK
Hospitals, Haematology Departm
Pharmaceutical Sciences, King’s
College of Pharmaceutical Scien
University, Hangzhou, China;
Institute of Science and Technolog
Mahidol University Hospital, Sal
Department of Biochemistry, Fa
University Hospital, Chiangmai, ThNontransferrin-bound iron (NTBI) is a heterogeneously speciated plasma iron, typi-
cally detectable when transferrin saturation (TfSat) exceeds 75%. Here, we examine
factors affecting NTBI levels by a recently discovered direct chelator-based (CP851)
fluorescent bead-linked flow-cytometric assay (bead-NTBI), compared with the
established indirect nitrilotriacetate (NTA) assay in 122 iron-overloaded patients,
including 64 on recent iron chelation therapy and 13 healthy volunteers. Both
methods correlated (r 5 0.57, P , 0.0001) but with low agreement, attributable to 2
major factors: (1) the NTA method, unlike the bead method, is highly dependent
on TfSat, with NTBI under-estimation at low TfSat and over-estimation once Tf is
saturated, (2) the bead method detects ,3-fold higher values than the NTA assay
in patients on recent deferiprone-containing chelation due to greater detection of
chelate complexes but lower values for patients on deferasirox. The optimal timing
of sample collection relative to chelation dosing requires further study. Patients
with splenectomy, high-storage iron, and increased erythropoiesis had greater
discrepancy between assays, consistent with differential access by both methods
to the NTBI pools associated with these clinical variables. The bead-NTBI assay has
advantages over the NTA assay, being less dependent on TfSat, hence of less
tendency for false-negative or false-positive values at low and high TfSat,
respectively. (Translational Research 2016;177:19–30)Abbreviations: AAS ¼ atomic absorption standard; AlAT ¼ alanine-aminotransferase; CFBs ¼
control fluorescent beads; CI ¼ confidence interval; CIC ¼ cardiac iron content; CSA ¼
congenital sideroblastic anemia; DBA ¼ Diamodn-Blackfan anemia; DCI ¼ directly chelatable
iron; DFO ¼ deferoxamine; DFP ¼ deferiprone; DFX ¼ deferasirox; ELISA ¼ enzyme-linked immu-
nosorbentassay; f.c.¼ final concentration; FBC¼ full bloodcount; IQR¼ interquartile range; LIC
¼ liver iron content; LPI ¼ labile plasma iron; MDS ¼ myelodysplastic syndrome;in Ma are co-first authors of this
Department, Cancer Institute,
; University College London
ent, London, UK; Institute of
College London, London, UK;
ce, Zhejiang Chinese Medical
Thalassemia Research Centre,
y for Research and Development,
aya, Nakhon Pathom, Thailand;
culty of Medicine, Chiang-Mai
ailand.
Submitted for publication December 25, 2015; revision submitted
May 3, 2016; accepted for publication May 31, 2016.
Reprint requests: Maciej W. Garbowski, Research Haematology
Department, UCL Cancer Institute, Paul O’Gorman Building, 72
Huntley Street, WC1E 6BT London, UK; e-mail: maciej.
garbowski@ucl.ac.uk.
1931-5244
 2016 The Authors. Published by Elsevier Inc. This is an open access
article under the CC BY license (http://creativecommons.org/licenses/
by/4.0/).
http://dx.doi.org/10.1016/j.trsl.2016.05.005
19
AT A GLANCE COMM
Garbowski MW, et al.
Background
Non-transferrin-bound iro
understood as a multispe
regulated separately from
and implicated in the
overload. The established
NTBI method is not op
transferrin bound iron fro
Translational Significanc
Here, we compared a
method with the NTA
diagnoses. The NTA a
overestimates NTBI at
saturations respectively,
being robust to effects
The greater specificity o
clarify links between rais
clinical consequences.
Translational Research
20 Garbowski et al November 2016MOPS¼ 3-(N-morpholino)propanesulfonic acid; NRBC¼ nucleated red blood cells; NTA¼ nitri-
lotriacetic acid; NTBI ¼ nontransferrin-bound iron; SD ¼ standard deviation; SF ¼ serum ferritin;
sTfR¼ soluble transferrin receptors; Tf¼ transferrin; TfSat¼ transferrin saturation; ULN¼ upper limit
of normal; UV ¼ ultravioletENTARY
n (NTBI) is increasingly
ciated plasma iron pool,
transferrin-bound iron
complications of iron
nitrilotriacetate (NTA)-
timal for distinguishing
m NTBI.
e
novel fluorescent bead
method, across clinical
ssay underestimates or
low- or high-transferrin
which the bead assay
of transferrin does not.
f the bead assay should
ed NTBI levels and theirINTRODUCTION
Plasma non-transferrin-bound iron (NTBI), first
described in 1978,1 is a pathological iron pool detect-
able when Tf saturation exceeds 75%.2-4 NTBI
appears when iron influx into the plasma compartment
exceeds iron efflux, for example, with iron overload,
ineffective erythropoiesis, or decreased transferrin
iron clearance in erythroid hypoplasia.5 NTBI is consid-
ered the main conduit of hepatic6-8 and extra-hepatic9-12
iron loading of tissues, under hemosiderotic conditions.
Quantitating NTBI is of value in understanding NTBI
generation under different pathophysiological settings5
but can also be potentially useful in the management
of iron-overloaded patients. However, using established
methods for NTBI quantitation, clear consensus, and
guidelines on how to use NTBI measurement in
patient management have yet to emerge. This is partly
because NTBI is multispeciated, consisting of a range
of iron-citrate,13,14 albumin-bound complexes,13 gly-
cated protein-iron complexes,15,16 or iron-chelate
complexes in recently chelated patients.17 Conse-
quently, it is unlikely that NTBI assays relying on
different principles will measure different NTBI speciesto the same extent. Hence, a consistent pattern of
association between NTBI values and clinical outcomes
has yet to emerge.
There is, therefore, a need to identify a robust and
well-characterized NTBI assay that can be applied in
a standardized manner in the management of iron-
overloaded patients. A range of NTBI methods used
previously differ considerably in their detection
principles and reported reference ranges.18 The most
long-standing and frequently reported NTBI method19
involves iron capture from NTBI by a high
concentration of a low affinity/specificity iron chelator,
nitrilotriacetic acid (NTA, 80 mM), followed by ultrafil-
tration and detection of NTA-iron by high-performance
liquid chromatography2,19 or spectrophotometrically.3
Another approach is measuring NTBI indirectly by
quantifying the redox-active subset of NTBI, which
has been termed the ‘labile plasma iron’ assay.20 A
further approach is measuring the directly chelatable
iron with a fluorophore-labeled high-affinity
chelator,18,21,22 but background fluorescence in
plasma may interfere with data interpretation. Most
recently, an adaptation of this approach was
described, using a high-affinity fluorescent chelator
CP851, covalently linked to magnetic beads with
fluorescence signal separated flow-cytometrically
from plasma autofluorescence.23 This potentially
circumvents the auto-fluorescence problem in the
plasma sample and problems related to the indirect
capture of NTBI by NTA.
The initial paper describing the bead method23 exam-
ined only 30 patients and did not, therefore, explore the
variables affecting the agreement between the NTA and
the bead method systematically. In particular, the effects
of TfSat, chelators, splenectomy status, and underlying
diagnosis were not explored. A recent round robin18
comparing various NTBI and labile plasma iron
methods on 60 patients reported their overall lack of
agreement in absolute values despite similar correla-
tions but did not specifically look at the agreement
between these 2 methods and could not, therefore,
comment on the possible reasons for their poor
agreement. Here, we compare levels of NTBI detected
by this assay with the NTA method in various clinical
conditions, including 122 iron-overloaded patients
with approximately half (n 5 64) receiving regular
chelation therapy. Part of this work was presented as
Abstract no. 241 at BioIron Conference Sep 6-10,
2015 in Zhejiang University, China.
Table I. Patient diagnoses, patient number correlation within diagnoses, and NTBI differences for groups with
n . 5
Diagnosis n Correlations* Grouped† NTBI comparison‡
Eb-thalassemia (Eb-thal) 44 0.68 (0.48–0.81)*** n 5 84, r 5 0.63 1.3 vs 1.0***
b-thalassemia major (b-TM) 24 0.72 (0.44–0.87)*** (0.49–0.74)*** 0.84 vs 0.82**
Thalassemia intermedia (TI) 11 0.5 (20.14 to 0.85) ns 20.06 vs 1.54 ns
Bart’s Hb 3 N/A N/A
a-Thalassemia 2
Hereditary HFE Hemochromatosis (HH) 9 0.64 (20.04 to 0.92) ns n 5 38, r 5 0.66 20.04 vs 21.67 ns
Sickle cell disease (SCD) 6 0.54 (20.36 to 0.92) ns (0.47 to 0.79)*** 20.07 vs 22.11 ns
Congenital sideroblastic anamia (CSA) 5
Myelodysplastic syndrome (MDS) 3
Diamond-Blackfan anemia (DBA) 2
Pyruvate kinase deficiency anemia 2
Aceruloplasminemia 2
Ferroportin disease 2
Red cell aplasia 1 N/A N/A
Sickle-E-b-thalassemia (SCD) 1
Congenital dyserythropoietic anemia 1
b-thalassemia-Hb Malay anemia 1
Hemolytic anemia 1
Spherocytosis 1
Atransferrinemia 1
Normal volunteers 13 0 (horizontal line) 20.1 vs 22.75***
Abbreviations: NTBI, nontransferrin-bound iron; ns, not significant.
P value , 0.0001***, ,0.001**, ,0.01*.
*Spearman correlation coefficient between NTA-NTBI and bead-NTBI, (95% CI), P value.
†Correlation coefficient between NTA-NTBI and bead-NTBI, (95% CI), P value in all thalassemia and all nonthalassemia diagnoses.
‡Comparison of median bead-NTBI vs NTA-NTBI, [uM], Wilcoxon test.
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Patients. One hundred twenty-two clinical blood
samples from iron-overloaded patients and 13 healthy
volunteers, obtained from 3 hospitals (affiliations 2, 4,
and 5), were analyzed using the CP851-NTBI assay
and NTA-NTBI assay. Diagnoses included are listed
in Table I. Ethical approval was obtained for the study
at the respective institutions where blood samples
were collected, and patients signed informed consent
forms before sample collection.
NTBI assays. NTA-NTBI assay. The NTA-NTBI method
previously described19 was adopted with minor modifi-
cations. Briefly, 0.02 mL of 800-mM NTA (at pH 5 7)
was added to 0.18-mL serum and allowed to stand for
30 minutes at 22

C. The solution was ultrafiltered using
Whatman Vectaspin ultracentrifugation devices
(30 kDa) at 12320g and the ultrafiltrate (0.02 mL)
injected directly onto an high-performance liquid
chromatography column (ChromSpher-ODS, 5 mM,
100 3 3mm, glass column fitted with an appropriate
guard column) equilibrated with 5% acetonitrile and
3-mM deferiprone (DFP) in 5-mM MOPS (pH 5 7.8).
The NTA-iron complex then exchanges to form the
DFP-iron complex detected at 460 nm by a Waters
996 photodiode array. Injecting standard concentrations
of iron prepared in 80-mM NTA generated a standardcurve. The 800-mM NTA solution used to treat the
samples and prepare the standards is treated with
2-mM iron to normalize the background iron that
contaminates reagents. This means that the zero
standard gives a positive signal because it contains the
added background iron as an NTA-complex. When
unsaturated transferrin is present in sera, this additional
background iron can be donated to vacant transferrin
sites resulting in a loss of the background signal and
yielding a negative NTBI value.
CP851 bead-NTBI assay. The standards for this assay
were prepared as follows: 1-mM iron-NTA complex
(1:2.5 molar ratio), prepared from 100-mM NTA and
18-mM atomic absorption standard iron solution, was
diluted with MilliQ water to a final concentration
(f.c.) between 0 and 100 mM. For the standard curve,
120 mL quantities of probe-labeled bead suspensions
were incubated with 20 mL of buffered NTA-iron solu-
tions of known concentration for 20 minutes at room
temperature, with subsequent addition of 20 mL normal
control serum (without free iron) and 40-mL parafor-
maldehyde (10% in MOPS) at 2% f.c. The suspensions
in sealed 96-well plates were incubated at 37

C for 16
hours with shaking before fluorescence measurement
by flow-cytometry. For serum samples of unknown
iron concentrations, 140 mL quantities of beads were
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with subsequent addition of 40-mL paraformaldehyde at
2% (f.c.). In this study, we used chelatable fluorescent
beads with normal human mixed serum as a control to
set up the fluorescence at 100% and the relative fluores-
cence of chelatable fluorescent beads with patient serum
was calculated accordingly. Measurements were carried
out on Beckman Coulter FC500 flow-cytometer and
analysis on Cell-Quest and FlowJo software. Gates
were based on dot-plots of untreated bead populations.
Median fluorescence of 10,000 events was recorded
and corrected for bead auto-fluorescence. A standard
curve was fitted with variable-slope sigmoidal dose-
response function.
Transferrin saturation. TfSat was determined by the
urea-gel method24 with band quantitation using Scion
Image software, normal reference range 16–56%
(mean 36%).
Routine blood test results and standard of medical care
monitoring. Hematology tests: full blood count and red
cell indices, reticulocytes, nucleated red blood cell,
serum alanine transaminase, bilirubin, and ferritin
were performed routinely in hospital laboratories;
sTfR was measured using ELISA (R&D Systems).
Liver iron content was obtained from liver T2*25 or
liver R2 Ferriscan,26 and cardiac iron content obtained
from cardiac T2*.27 Medical records review provided
information about chelation therapy, transfusion, and
splenectomy status.
Statistics. The data were presented descriptively using
mean6 standard deviation (SD) or median6 interquar-
tile range where appropriate, differences between
subgroups were calculated using Wilcoxon test or
paired t-test, dependent on distribution assumptions.
Ninety-five percent confidence interval follows slope
and Spearman or Pearson correlation coefficient value
in brackets. Graphpad Prism, Ver. 6.0 plots were used
for slope comparison and Bland-Altman plots28 to
illustrate agreement between methods. A P , 0.05
was deemed statistically significant.
RESULTS
Correlations, distributions, and agreement between
NTA-NTBI and bead-NTBI were first examined. The
TfSat effects on measured values were compared,
followed by the effects of chelation therapy, erythropoi-
esis, storage iron, and splenectomy status on NTBI
measured by both methods.
Correlation and agreement of the 2 assays in all
samples. There was a medium-strong correlation
between bead-NTBI and NTA-NTBI for all samples
(Fig 1A). Because negative values were obtained in
the NTA assay, the graph was replotted treating all
negative values as zero (Fig 1C). In Bland-Altmananalysis (Fig 1B and D), the differences between
methods notably increased at mean NTBI.2.5 mM
being even greater above mean values of 4 mM. For
mean values between ,1 and 4 mM, the bias is not
constant, being negative at ,0 mM (NTA method less
than bead method) and positive between 0 and 2 mM
(bead higher than NTA). Treating negative values as
zero does not improve agreement (Fig 1D), suggesting
that negative values are not the main reason for the
lack of agreement.
The distribution of NTBI values by the 2 methods. The
NTBI distributions for both methods differ considerably
between the assays (Fig 2A). With the NTA-NTBI
(black) there is a clear population of negative values
that is absent with the bead-NTBI (red). There is then
a second population of positive NTA values
(mode 5 1.5 mM) that is absent with the bead-NTBI
where the mode 5 0 mM. Finally, there is a long-
positive tail of high-bead-NTBI up to 14 mM that is
absent with the NTA method. The further analysis
below aims to determine the meaning of these
distributional differences.
Relationship of TfSat to NTBI values by the 2
methods. NTBI values are related to TfSat by NTA assay
but not bead assay. The relationship of NTBI values by
both methods to TfSat is presented in the inset of
Fig 2A. TfSat has a strong relationship to the NTA-
NTBI over its negative range, but not to the bead-NTBI.
In particular, the NTA-NTBI values fall with decreasing
TfSat, unlike with the bead assay, with the NTA-NTBI
becoming negative for TfSat,80%, but no such effect is
seen with the bead method, which confirms previously
published results ona smaller groupofpatients.18Because
of the relationship of NTBI to TfSat by the NTA method
and not the bead method, we examined the distribution of
TfSat shown in Fig 2B for the bead-NTBI (left) and
NTA-NTBI (right) for samples where positive (red) or
negative (black) NTBI values were obtained. It appears
that whereas with the bead-NTBI TfSat has a similar
(P 5 0.84) distribution for patients with positive or
negative NTBI values, by contrast, the negative NTA-
NTBI are largely confined to patients with TfSat,60%
and the positive values to patients with TfSat.80%
(P , 0.0001). This supports the relevance of low TfSat
to negative NTA-NTBI but not bead-NTBI values.
Relevance of high TfSat to false-positive values with NTA
assay. ‘True-negative’ bead-NTBI values (below upper
limit of normal [ULN] 5 0.68 mM i.e., 33SD above
normal control mean 5 20.1 mM, SD 5 0.26 mM,
marked as dashed line in Fig 1A) were plotted against
NTA-NTBI with the point size reflecting TfSat
(Fig 2D, note Fig 2C and D are derived from Fig 1A).
Positive NTA-NTBI associates exclusively with high
TfSat, whereas negative NTA-NTBI almost exclusively
Fig 1. Comparison of NTA and beads method for NTBI measurement. (A) NTA and beads (CP851) methods
plotted for all samples using the original scale. Correlation coefficient r5 0.57 (0.44–0.68) P, 0.0001 (B) Agree-
ment shown using Bland-Altman analysis of difference (DNTBI 5 NTA-CP851) vs. mean of the 2 methods on
data from panel A with bias 21.21 6 2.25 mM and 95% LoA (limits of agreement) from 25.6 to 3.2 mM.
(C) Both methods for NTBI measurement plotted as in panel A but with negative values by both methods shown
as zero (absent NTBI) Correlation coefficient r 5 0.6 (0.48–0.7) P , 0.0001. (D) Agreement shown using
difference vs. mean Bland-Altman analysis of data in panel C, bias 20.56 6 2.1 mM, 95% LoA 24.68 to
3.56 mM. NTBI, nontransferrin-bound iron; NTA, nitrilotriacetate.
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P , 0.0001). This means that the positive values by
the NTA method that are negative by the bead method
associate with high TfSat and are ‘false-positive’. This
is consistent with iron being stripped off holotransferrin
by NTA and not by CP851 (discussed). In contrast, no
such distributional TfSat differences were seen between
the negative and positive bead-NTBI values (on both
sides of the red dotted line, Fig 2B and D). It is also
possible that for other NTA-NTBI assays (N3 in the
round robin,18 or using Co or Mn blocking29) the
relationship with the TfSat may be different.
Relevance of low TfSat to false-negative values with NTA
assay. The NTA-NTBI values were plotted against ‘true-
positive’ bead-NTBI values (above ULN, Fig 2C, mark
the range change on the x-axis in Fig 2C vs. 2D) with
the point size reflecting TfSat. It appears that the ‘true-
positive’ bead-NTBI is also typically positive by the
NTA method only when associated with high TfSat. In
the small number of values where the NTA-NTBI is
negative, TfSat is low. Thus ‘false-negative’ NTA-NTBI
values occur only in the presence of apotransferrin.Relationship of chelation therapy and NTBI values by
both methods. The presence of iron-chelate complexes
or iron-free chelator could in principle influence the
assay behavior in vitro.17,23,30 We examined these
potential effects by comparing values in regularly
chelated patients with those not receiving chelation.
Both NTBI assays are plotted for chelated and
unchelated patients in Fig 3A. The range of values
differs in the upper (no chelation) and lower panels
(recent chelation), particularly for the bead-NTBI
(red), where there is a ‘tail’ of high values (5–15 mM)
in chelated patients (Fig 3B and D). In principle, this
could represent iron-chelate complexes detected as
bead-NTBI. With the NTA-NTBI (black), the
difference between chelated and unchelated patients is
subtler, but it appears that the proportion of patients
with negative values decreases, whereas that of patients
with slightly positive values (up to 2 mM) increases on
chelation (Fig 3B and E). This could again represent
the effects of iron-chelate complexes on the assays.
To investigate this in more detail, the values obtained
with both assays were plotted for patients on different
Fig 2. Distribution of CP851-NTBI, NTA-NTBI, and transferrin saturation values with analysis of false-positive
and false-negative NTA-NTBI values. (A) Comparing frequency distribution histograms of CP851-NTBI (red)
and NTA-NTBI (black) in 135 pairs; frequency (number of values) of NTBI per interval of 0.5 mM (bin size) is
shown. Inset shows the relationship between NTBI level and urea-gel TfSat for both methods: CP851-NTBI
(red) and NTA-NTBI (black); best-fit linear regression slope differences (P , 0.0001) with 100% TfSat points
excluded from regression. (B) Plots of Tf saturation on x-axis (in 10% increments, bin center) against frequency
of TfSat observations (y-axis) for NTBI values , or . 0 mM. The left panel shows bead method and right panel
NTA method. The TfSat distributions for NTBI values. 0 mM are significantly different from those under 0 mM
by the NTAmethod only (Mann-Whitney test); at low TfSat negative NTBI values are significantly more likely by
NTA method and at high TfSat positive NTBI values are more likely by NTA method. These differences are not
apparent by the beads method. (C) The plot of NTA-NTBI values vs. true-positive bead-NTBI values (above
ULN5 0.68 mM—dashed line in Figure 1A), the size of the point reflects TfSat. Data in the red-shaded box (below
ULN) are shown in panel D. (D) The plot of NTA-NTBI vs. true-negative bead-NTBI (red-shaded box in panel C
corresponds to the data to the left of the dashed line in Figure 1A) with point size reflecting TfSat. Mean TfSat for
NTA values .0 mM was 93%, 19/36 were 100%, range 62–100%, median, 25th and 75th percentile: 100, 91,
100%. Mean TfSat for NTA values ,0 mM was 41.5%, 1/46 was 100%, range 11–100%, median, 25th and
75th percentile: 39.5, 31.5, 46%. NTBI, nontransferrin-bound iron; NTA, nitrilotriacetate; TfSat, transferrin
saturation.
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on the same samples with the bead assay (max. 15 mM)
are about 3-fold higher than with the NTA assay (max.
5 mM) for deferiprone or combination (desferrioxamine
1 deferiprone) treated patients but not for deferasirox
(DFX), where bead-NTBI values are actually lower
than NTA-NTBI. Patients receiving desferrioxamine
usually show about 2 to 3-fold higher values with
the bead assay than the NTA-NTBI. NTBI levels
correlated within the desferrioxamine (0.47 (0.01,
0.77), P 5 0.05), and the deferiprone (0.62, (0.34,
0.81) P 5 0.0003) groups, but without agreement ofabsolute values, whereas in the DFX patients correlation
was absent.
Differences in patient sampling on DFX and deferi-
prone offer a partial explanation. All patients receiving
DFX had a 72-hour chelation washout, strictly observed
before sampling, making the presence of the contami-
nating iron-DFX complexes unlikely. By contrast, in
most of the deferiprone-treated patient samples, where
72-hour washout was not observed, the iron-chelate
complexes would be expected to be present.17,23 It
appears that the complexes of deferiprone are more
readily detectable as bead-NTBI than NTA-NTBI but
Fig 3. Effect of chelation on method agreement. (A). Comparison of NTBI distributions in patients not chelated
(upper panel) and chelated (lower panel), red symbols show the bead CP851 assay and black symbols the NTA
assay. (B) Comparison of NTA method vs. bead method in patients with (black) and without (red) chelation, of
the outliers marked only the chelation ones were excluded from analysis in panels (C–E). (C) Comparison of TfSat
distributions in chelated and unchelated patients seen in B, Mann–Whitney test. (D) Comparison of CP851-NTBI
in chelated and unchelated patients seen in B, Mann–Whitney test (E) Comparison of NTA-NTBI in chelated and
unchelated patients seen in B, Mann–Whitney test. (F) NTAmethod vs bead method in patients on deferasirox, no
correlation (ns) (G) NTA method vs bead method in patients on desferrioxamine, correlation coefficient r5 0.47
(0.01–0.77), P5 0.05. (H) NTAmethod vs beadmethod in patients on deferiprone, correlation coefficient r5 0.63
(0.34–0.81), P5 0.0003. (I) NTA method vs bead method in patients on combination therapy of deferiprone and
desferrioxamine, correlation coefficient r5 0.78 (0.3–0.95), P5 0.0076. NTBI, nontransferrin-bound iron; NTA,
nitrilotriacetate; TfSat, transferrin saturation.
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are probably partly responsible for it. The detection of
high levels by the bead assay in 2 patients on desferriox-
amine (Fig 3G) is not predicted from in vitro evaluation
of the bead assay23 and is difficult to explain unless
patients were taking deferiprone.
Other factors affecting relationships between
assays. Using univariate analysis, we investigated the
effects of diagnoses, transfusion status, erythropoiesis
(by sTfR), splenectomy, and storage iron, on the levels
of NTBI by both assays. There was no relationship
between NTBI and diagnoses, but both NTBI methods
were differentially affected by high-erythropoieticstatus, splenectomy, and high-iron storage (as detailed
in Supplementary Material: Subgroup univariate
analysis, Table SI, Figs S1–S4).
Multiple regression. Multiple linear regression models
were built to test which predictors explain differences
between the NTA-NTBI and the bead-NTBI. The
same or additional predictors may resurface as
relevant when the absolute difference (bias) between
methods is modeled, and this was attempted as a
control analysis. Furthermore, we have modeled
transferrin saturation using the same set of potential
predictors as for the other models (Table II). The
bead-NTBI model explained 25% of the variability in
Table II. Multiple regression models for NTA-NTBI, CP851-NTBI, bias (CP851-NTA), and transferrin saturation
Model NTA-NTBI CP851-NTBI Bias TfSat
Adjusted r-square 0.75*** 0.26*** 0.24*** 0.42***
n 101 120 117 100
Constant 23.890.27*** 21.370.59* 2.160.62** 42.175.01***
TfSat 0.0560.003 (0.86)*** 0.0280.007 (0.3)*** 20.0260.007 (20.34)***
Splenectomy yes 5 1 0.510.2 (0.13)* 1.320.47 (0.23)** 0.860.41 (0.18)*
Thalassemia yes 5 1 31.195.67 (0.52)***
Eb-thal yes 5 1 11.64.75 (0.21)*
MDS yes 5 1 42.115.3 (0.21)**
CSA yes 5 1 42.510.4 (0.33)***
DBA yes 5 1 47.815.2 (0.24)**
SF [ug/L] 0.0060.001 (0.31)***
sTfR [nM] 20.0030.001 (20.12)*
Chelation yes 5 1 1.250.45 (0.27)**
DFO 1 DFP yes 5 1 2.290.8 (0.23)** 1.590.71 (0.19)*
DFO yes 5 1
DFX yes 5 1 21.810.61(20.26)**
Normal yes 5 1 1.420.7 (0.19)*
Abbreviations: NTBI, nontransferrin-bound iron; NTA, nitrilotriacetate; TfSat, transferrin saturation; MDS, myelodysplastic syndrome; CSA,
congenital sideroblastic anemia; DBA, Diamodn-Blackfan anemia; DFO, deferoxamine; DFP, deferiprone; DFX, deferasirox.
An empty cell indicates that predictor was not significant in a particular model. Statistics for predictors (italics) are given as absolute regression
coefficient, its standard deviation in subscript, adjusted regression coefficient in brackets, followed by the significance of the predictor
(***,0.0001, **,0.001, *,0.05). All other predictors insignificant (LIC, cardiac T2*, SGOT, SGPT, Ret, NRBC, Plt, WBC, Hb, Hct, MCV, MCH,
MCHC, bilirubin, transfusion). Multiple linear regression on SPSS version 22 was used.
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(DFO) 1 DFP as positive predictors. The NTA-NTBI
model explained .75% of the variability in NTBI,
with TfSat, splenectomy as positive, and sTfR as
negative predictors. The bias model, that is, the
difference CP851-NTBI less NTA-NTBI, was
predicted negatively by TfSat and DFX, and positively
by splenectomy, DFO 1 DFP, chelation (yes/no), and
‘‘normal’’, in a model explaining 24% of the NTBI
variability. The TfSat model explained 42% of the
NTBI variability using thalassemia, Eb-thalassemia,
myelodysplastic syndrome, congenital sideroblastic
anemia, Diamond-Blackfan anemia, and serum ferritin
as positive predictors.DISCUSSION
This study examined a range of iron-overloaded pa-
tients with and without iron chelation, which allowed
comparison of the established NTA-based NTBI assay
(NTA-NTBI) with a novel fluorescent bead-based assay
(bead-NTBI) under a wide range of clinical conditions.
Overall, although significant correlations exist between
both methods, absolute values differ with wide 95%
limits of agreement, consistent with the recent round-
robin of NTBI assays.18 Here, by comparing values in
a large number of iron-overloaded patients, we examine
how both assays are differently affected by identifiable
variables. These are relevant to the application and
interpretation of both NTBI assays in specific patientpopulations. Two systematic differences between the
assays have been identified. First, the NTA-NTBI is
highly affected by TfSat, leading to under-estimations
at low TfSat and over-estimation once transferrin is
saturated. By contrast, the bead-NTBI is less dependent
on either high or low TfSat. Second, while both assays
give increased NTBI values in recently deferiprone-
treated patients, due to detection of chelate-iron
complexes, this effect is more pronounced with the
bead-NTBI, leading to a further lack of agreement
between the 2 assays.
Inspection of the NTBI distribution histograms for
both assays, combined with the knowledge of the
contrasting chelating properties of NTA and the
hexadentate CP851 used in the bead method, provides
insight into why the agreement is not high. With the
NTA-NTBI, 2 major peaks are seen, first centering on
22.5 mM, and the second peak on 1.5 mM skewed right-
ward. With the bead-NTBI, these peaks are essentially
absent with most low values clustered around zero and
with a much more pronounced right skew for positive
NTBI. These differences are consistent with the known
properties of the ‘capture’ mechanisms of the assay che-
lators. Negative NTBI values obtained with the NTA
method have been attributed to shuttling of iron present
in 80-mM NTA onto apotransferrin during the initial
incubation.2,31,32 This shuttling iron donation effect,
due the greater stability of the hexadentate bead
chelators, is absent in the bead method.23 Eighty-mM
NTA not only donates chelated iron to iron-binding
Translational Research
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transferrin in a time- and concentration-dependent
manner,3 so that at 30 minutes 80-mM NTA mobilized
1–2% of transferrin iron (physiological concentration,
TfSat 5 50%). This represents 0.35–0.7-mM
transferrin-bound iron potentially detected as ‘NTBI’
but could be as much as 1.4 mM with TfSat 5 100%
in our patients. Others noted similar effects.33,34
The impact of such high-iron removal from trans-
ferrin has not been previously characterized, and here
the comparison with the bead method, where iron is
not stripped from holotransferrin (,0.2%) by the hexa-
dentate chelator,23 demonstrates this effect more
clearly. Given the robustness toward transferrin of the
bead-assay, it can be used as a reference in an attempt
to examine transferrin dependence of the NTA-
method. Closer inspection of the normal and patholog-
ical bead-NTBI distributions suggests a cut-off above
which values can be regarded as ‘true-positive’ and
provides supportive evidence for the mechanisms
underlying ‘false-positive’ and ‘false-negative’ values
obtained with the NTA assay. With the bead-NTBI,
values centring in the narrow dominant peak around
the mode 20.04 mM (Fig 2A) are likely to represent
an absence of true NTBI, given the comparable spread
around the mean of the normal serum samples
(20.1 6 0.26 mM with ULN of 0.68 mM mean13SD,
SD 5 0.26 mM, Figs 2A and S2K). Bead-NTBI
values . 0.68 mM are therefore likely to represent
‘true-positive’ NTBI. Clearly ‘false-negative’ values
by the NTAmethod would then be those negative values
obtained when the bead assay gives positive
values . 0.68 mM. When this was checked, all the
‘false-negative’ NTA values occurred in samples with
nonsaturated transferrin (45, 18, 48%, Fig 2C) where
the predicted percentage of apotransferrin that can act
as an acceptor for iron shuttled by NTA, approaches
30%, 65%, and 28%, respectively.35 By contrast,
‘false-positive’ NTA-NTBI would be those positive
values that correspond to bead-NTBI,0.68 mM. All
such ‘false-positive’ NTA values had highly saturated
transferrin (mean 93%, range 62–100%) supporting
the concept that such ‘false-positive’ NTBI values are
obtained from the scavenging of iron from highly
saturated transferrin.
The second factor, contributing to differences
between both assays, is the effect of iron chelators or
their iron complexes. With the NTA-NTBI, iron-free
chelators present in plasma can act as acceptors for
NTA-bound iron, potentially leading to the NTBI
underestimation.31,32 This donation can be blocked in
the NTA assay by adding an excess of aluminum to
samples before processing.30,32 This is not a problem
for the bead-NTBI, as the greater stability of theCP851-iron complex prevents iron donation to iron-
free chelators in samples.23 The iron complexes of
some chelators can also potentially interfere with the
NTBI determination: with the NTA-method, the
deferiprone-iron complexes are detected as ‘NTBI’ up
to 1 week after drug cessation.17 In principle, the bead
assay can also detect such complexes of deferiprone,23
and indeed our findings here suggest that these are
detected to a greater extent than with the NTA assay
(Fig 3G–I).
Owing to the high stability of ferrioxamine (1:1
iron(III):desferrioxamine), the bead-assay removes
only a negligible amount of iron from DFO-iron
complexes.23 Given this observation, it is difficult to
explain the presence of 2 outliers in Fig 3G, and perhaps
the iron-binding DFOmetabolites should be considered.
In the DFX-treated patients, NTBI is lower than in the
other chelators using both assays but especially with
the bead-assay, with values ,1 mM (Fig 3F). This
may reflect superior NTBI removal with DFX or that
patients in this group had 72-hour washout from
chelators, allowing full clearance of DFX-iron
complexes. These complexes may clear more rapidly
than those of deferiprone which are measurable
.1 week after the last chelation dose.17 Thus in patients
who are on regular chelation therapy, interpretation of
NTBI values needs to be made concerning the timing
of sampling, particularly with the bead-assay which
has high affinity for iron-deferiprone and iron-DFX
complexes.23
Clinical factors potentially affecting the detection
levels of both NTBI assays were examined. Underlying
diagnoses in themselves did not show significant
differences between assays (Table II), but the extent of
erythropoiesis did (Fig S4A): higher sTfR levels (and
hence greater erythropoiesis and iron removal from
transferrin) reduce NTA-NTBI, but not bead-NTBI
values. As lower TfSat associates with decreased
NTBI values due to NTA shuttling iron onto transferrin,
clearance of transferrin-bound iron by enhanced
erythropoiesis may increase iron shuttling by NTA
and hence lower measured values. Negative prediction
of the bias by TfSat suggests that the methods are
differentially affected by TfSat, consistent with the
methodological dependence of the NTA method on
TfSat where NTA strips iron from transferrin, with
NTBI overestimation rendering the bias lower.
Likewise, DFX negatively predicts the bias because it
affects only the bead-NTBI (Fig 3F), and this is a key
issue we are currently investigating. Normal status
increases the bias by rendering NTA values
negative (ApoTf). Chelation increases the difference
because it increases the bead-NTBI more than
the NTA-NTBI when detecting deferiprone-iron
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method using multivariate analysis and also associates
with higher NTBI (by 0.5 or 1.3 mM, Table II). That
splenectomy predicts bias is interesting while at the
same time being a positive predictor of both methods
separately because it implies that bead assay detects
more NTBI in splenectomized patients rather than that
the NTA method detects less (Fig S4B), suggesting it
differentially affects the manner in which both methods
may detect NTBI (splenectomy-dependent NTBI speci-
ation differences). Higher NTA-NTBI in splenectom-
ized TI patients was reported36 as was a greater risk of
myocardial iron deposition after splenectomy.37 The
mechanism for higher NTBI after splenectomy is un-
clear, but, we suggest, may relate to erythrocyte destruc-
tion being diverted from the spleen to the bone marrow.
With relatively hypoxic bone marrow environment,
oxidation from Fe21 to Fe31 will have slower kinetics,
hence slower iron binding to transferrin, and a greater
propensity to plasma NTBI formation. Similarly, higher
levels of iron overload (serum ferritin or liver iron
content) are associated with higher bead-NTBI than
NTA-NTBI values, suggesting the bead method may
detect some iron species associated with iron overload
that are relatively unavailable for capture using the
NTA method.
Unlike the NTBI values by either method, the TfSat is
notably predicted by diagnoses and ferritin in our
cohort. In the explanation of the ferritin effect on TfSat
but not on NTBI (the latter also reported recently18), we
distinguished plasma iron compartment into the trans-
ferrin part, changing dynamically below 100% (TBI),
and into NTBI part, typically present when transferrin
is 100% saturated (TfSat not changing dynamically
anymore). This means that ferritin as a predictor of
TfSat marks the independent effect of the degree of tis-
sue iron overload on the changes in the transferrin part
of plasma iron compartment (i.e., TfSat increases when
ferritin increases), but such independent effect on the
level of NTBI, once TfSat is saturated, is absent. In
other words, if NTBI is considered in a continuum
with TBI above the saturation point of Tf, it is evident
that plasma iron above the saturation point of Tf
(NTBI) does not associate with ferritin (and therefore
with iron overload), whereas the plasma iron on trans-
ferrin does. This is very interesting to us because it
may suggest that regulation of serum iron varies by
compartment: NTBI is less dependent for its generation
and persistence on iron overload per se, and likely more
dependent on other factors such as those that determine
its removal rather than generation (tissue uptake-
erythroid, hepatic).5,38 Finally, that sTfR does not
predict TfSat but does negatively predict NTBI
implies that the rate of transferrin off-loading in themarrow may affect the NTBI compartment without
apotransferrin being detected peripherally.38
In conclusion, we have identified that the TfSat in the
blood sample affects values obtained with the NTA
assay to a greater extent than with the bead assay.
This results from iron donation to apotransferrin by
NTA and/or stripping of iron from saturated transferrin
by NTA. Neither of these effects is significant with the
bead assay, which may, therefore, be more specific for
true NTBI determination. These findings are consistent
with first principles, namely differential access to trans-
ferrin iron of both methods, but other mechanisms may
be involved, which require further systematic study. The
presence of iron-chelate complexes in patients on
chelation, particularly with deferiprone, increases
values obtained with the bead assay more than with
the NTA assay. Recent chelation history (minimum a
week before blood sampling) needs accounting for
when interpreting NTBI values obtained with either
method. Other differences between the assays regarding
the effects of splenectomy, levels of iron overload and
endogenous erythropoiesis are consistent with both
assays differentially accessing NTBI pools that vary
with these clinical variables. Future work will need to
identify whether NTBI values obtained with the bead
assay are more clinically predictive of trends, such as
myocardial iron deposition than with the NTA assay.
The effects of sample timing in relation to currently
available chelation therapies need to be further defined
with both assays. We recommend using both methods in
NTBI research because the NTA-NTBI and the
bead-NTBI do not detect exactly the same species of
NTBI, and that further research is necessary to describe
NTBI speciation in greater detail before a recommenda-
tion can be made (if at all) which method should the
researchers rely on.ACKNOWLEDGMENTS
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Subgroup Univariate Analysis
NTBI by underlying diagnoses. The relationship be-
tween both assayswas broadly similar across different pa-
tient diagnoses although median bead-nontransferrin-
bound iron (NTBI) values were typically higher than
nitrilotriacetate (NTA)-NTBI for Eb-thal, b-TM, SCD,
HH, and healthy controls (Fig S1, Table I). Significant
correlations but poor agreement between both NTBI
methods were seen for Eb-thal, b-TM, and all
thalassemias, with negative values by both methods
treated as zero (Fig S1, Table SI). Other diagnoses were
not sufficiently represented to draw correlation or
agreement conclusions, however in nonthalassemic
group as a whole the correlation was significant
(Table I). Normal control samples neither correlated nor
agreed between the 2 assays but their bias could be
corrected for (Fig S2L).
Transfusion. In transfused patients, both the methods
correlated but nontransfused patients correlation was
weak. Slopes were significant in both the groups, but
only intercepts differed (Table SI). Significant effect
of transfusion seems to be limited to high TfSat as
only samples with TfSat.90% show significant
positive slope among transfused patients (Fig S3).
Bead-NTBI was higher than NTA-NTBI in transfused
and untransfused patients (Table SI).
Erythropoiesis. High- and low-erythropoietic states
were judged by soluble transferrin receptor (sTfR)
levels above (high) and below (low-normal) 28.1 nM
(ULN). NTBI methods correlated, the slopes were
significantly positive but differed from one another,
for high- and low-normal erythropoietic states. The
NTA assay detected less NTBI relative to the beadassay for patients with high erythropoiesis compared
with those with low-normal levels of erythropoiesis
(Table SI, Fig S4A). Because a high-erythropoietic
rate will increase iron clearance from transferrin, this
is predicted to free up iron binding sites on transferrin
thus increasing iron shuttling onto these sites and
hence lower levels with the NTA assay.
Splenectomy. In patients with and without splenec-
tomy, the methods correlated well with positive slopes
that differed significantly: bead-NTBI being higher,
and the difference between methods being greater in
splenectomized than unsplenectomized patient
(Fig S4B, Table SI).
Storage iron. For high- and low-ferritin patient groups
(above or below 1500 mg/L), methods correlated well
with significantly different positive slopes. There was
greater discrepancy between NTBI levels in the high-
ferritin than the low-ferritin group (Fig S4C, Table
SI): for similar CP851-NTBI values, NTA method
gives lower NTBI values in the former and higher in
the latter group above about 2-mM bead-NTBI
threshold. Methods were also compared in liver iron
content (LIC) groups below and above 12 mg/gdw
(SF 5 1500mg/L corresponds in our study to
LIC 5 12 mg/gdw) showing medium correlation and
significantly different positive slopes. In high LIC
group, discrepancy between methods was greater
(Fig S4D, Table SI). NTBI differences were
insignificant on direct comparison: not all patients had
LIC available (n 5 35 vs n 5 109 for ferritin), so
comparison may be underpowered to detect
differences. Taken together, these findings show that
at high-storage iron (LIC or SF) the extent to which
bead-NTBI values exceed NTA-NTBI is increased.
Table SI. Subgroup analysis: correlations, slope comparison, and NTBI differences between transfusion,
erythropoiesis, splenectomy, storage iron and chelator subgroups
Subgroup* Correlation† Slope‡ Test§ NTBI compjj
All samples 0.61 (0.49–0.71),*** 1.5 6 2.59 mM vs 0.94 6 1.13 mM,*
Transfused 0.57 (0.4–0.7),*** 0.31 (0.21–0.41),*** ns, int** 2.04 6 2.99 mM vs 0.76 6 1.56 mM,***
Untrasfused 0.31 (0.02–0.55),* 0.83 (0.05–1.6),* 0.14 6 0.71 mM vs -0.83 6 1.91 mM,**
High sTfR 0.63 (0.48–0.74),*** 0.25 (0.18–0.31),*** * 1.8 6 2.9 mM vs 1.1 6 1.16 mM,*
Low-normal sTfR 0.6 (0.28–0.8),** 0.83 (0.36–1.29),** 0.44 6 0.83 mM vs 0.7 6 1.13 mM, ns
Splenectomy 0.5 (0.24–0.69),** 0.14 (0.06–0.21),** *** 2.97 6 3.7 mM vs 1.26 6 1.02 mM,**
No splenectomy 0.68 (0.55–0.79),*** 0.44 (0.33–0.54),*** 0.84 6 1.7 mM vs 0.73 6 1.1 mM, ns
SF . 1500mg/L 0.55 (0.32–0.72),*** 0.17 (0.1–0.25),*** * 0.82 6 1.66 mM vs 0.71 6 1.03 mM, ns
SF , 1500mg/L 0.65 (0.47–0.78),*** 0.41 (0.280.54),*** 2.83 6 3.45 mM vs 1.49 6 1.07 mM,*
LIC.12 0.77 (0.48–0.91),*** 1.05 (0.6–1.49),*** * 0.45 6 0.96 mM vs 0.86 6 1.31 mM, ns
LIC,12 0.66 (0.24–0.87),* 0.42 (0.14–0.69),* 0.63 6 1.67 mM vs 1.19 6 1.06 mM, ns
Abbreviations: ns, not significant; LIC, liver iron content; SF, serum ferritin; sTfR, soluble transferrin receptors; NTBI, nontransferrin-bound iron.
P-value ,0.0001***, ,0.001**, ,0.01*.
*Conditions where bead-NTBI and NTA-NTBI were compared.
†Pearson correlation coefficient (95% CI), P value.
‡Slope (95% CI), P value.
§Comparison of slopes P-value or when ns, the intercept (int) comparison P-value.
jjMean NTBI comparison CP851 vs NTA (95% CI), t test p.
Fig S1. Box and whisker plot (range) of NTBI in healthy controls and various conditions of iron overload using a
standard analytical method (NTA-NTBI) and the proposed bead-based NTBI method. NTA, nitrilotriacetate;
NTBI, nontransferrin-bound iron.
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Fig S2. Comparison and Bland-Altman analysis of agreement of NTA and CP851-NTBI methods in different
diagnosis groups. Negative values by both methods have been treated as zero. (A-B) all diagnoses; slope
P , 0.0001. (C-D) beta-thalassemia major; slope P , 0.0001. (E-F) E-beta-thalassemia; slope P , 0.0001.
(G-H) thalassemia intermedia; slope not significant. (I-J) all thalassemias; slope P , 0.0001. (K-L) normal vol-
unteers; slope not significant. All Bland-Altman analyses show lack of acceptable agreement except for the normal
samples where the low-scatter systematic bias could be corrected for using the formula (239.1 6 35.12[%]
*avgNTBI[uM]1527.3 6 50[%]) (27). NTBI, nontransferrin-bound iron; NTA, nitrilotriacetate.
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Fig S3. The effect of transferrin saturation on method agreement in transfused and untransfused patients. (A) Plot
of both NTBI methods in transfused (black) and untransfused patients (red). (B) Plot of both NTBI methods in
untransfused patients (red in panel A). Samples with TfSat.90% are now shown in red and thosewith TfSat,90%
in black. (C) Both NTBI methods plotted in transfused patients (black in panel A), here further grouped according
to TfSat in sample: with significant slope in TfSat.90% (red, P , 0.0001) and insignificant in TfSat,90%
(black). (D) Both methods plotted for transfused patients with TfSat,90% show insignificant slope (black sym-
bols from panel E magnified). TfSat, transferrin saturation; NTBI, nontransferrin-bound iron.
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Fig S4. Comparison of NTA-NTBI and CP851-NTBI methods in groups with different erythropoietic, spleen,
ferritin, and LIC status. (A) Slope comparison between high- and low-normal erythropoietic status defined by sol-
uble transferrin receptor: both slopes are significant (0.25 6 0.03, P , 0.0001 and 0.82 6 0.22, P 5 0.001) and
different (P5 0.01); patients mean sTfR (n5 117) was 93.466 68.1 nM (median 88.24, IQR 30.1–133.2, range
5.38–332.5; B) Slope comparison between patients with and without splenectomy: both slopes are significant
(0.14 6 0.04, P 5 0.0005, and 0.44 6 0.05, P , 0.0001) and different (P , 0.0001). (C) Slope comparison be-
tween low- and high-ferritin groups (1500mg/L): both slopes are significant (0.41 6 0.06 and 0.17 6 0.04, both
P , 0.0001) and different (P , 0.0013). (D) Slope comparison in low- and high-LIC groups (12 mg/gdw): both
slopes significant (1.056 0.21, P5 0.0001 and 0.426 0.13, P5 0.006) and different (P5 0.015). LIC, liver iron
content; sTfR, soluble transferrin receptors; NTBI, nontransferrin-bound iron; NTA, nitrilotriacetate; IQR, inter-
quartile range.
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